Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy
Victor A. Chow, Ajay K. Gopal, Jordan Gauthier, Yolanda D. Tseng, Cameron J. Turtle, David G. Maloney, Mazyar Shadman
Abstract
Key Points No meaningful responses were observed when axicabtagene ciloleucel was used for progression after a different CD19-directed CAR T cell. Further research is needed to understand how to sequence cell-based therapies for relapsed/refractory large B-cell lymphomas.
Topics & Concepts
CD19CAR T-cell therapyRefractory (planetary science)MedicineLymphomaOncologyCancer researchInternal medicineChimeric antigen receptorImmunotherapyImmunologyAntigenCancerBiologyAstrobiologyCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy research